I'm not sure the paperwork would be huge. Most ex-US markets have a single point of purchase/negotiation with the government agency. Companies already are required to disclose cost data. While I would expect them to fight it tooth and nail regardless, I doubt the paperwork burden would be that much different than the intra-US rules we currently have.
Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr